PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Private clinic launches UK’s first MRIdian radiotherapy machine

Cancer patients can from today potentially access the UK’s first MRIdian machine, a new radiotherapy treatment said to reduce treatment time and cause fewer side effects.

The technology combines magnetic resonance imaging (MRI) techniques with high precision radiotherapy beams, allowing clinicians to adapt treatment to take account of tumour movement in real time, which reduces the amount of healthy tissue hit by radiotherapy, thereby lowering the risk of side effects.

As the machine enables higher doses to certain tumours than would be possible using conventional radiotherapy treatment time can be shortened; with conventional radiotherapy, early stage prostate cancer patients typically require at least 20 treatments – with the MRIdian it can be as low as five.

The MRIdian has been launched by private cancer care provider GenesisCare at its centre in Oxford but, as part of a partnership with the University of Oxford, NHS patients will also be able to access this treatment as part of trials.

“Treatment on the MRIdian allows us to be virtually 100% accurate, 100% of the time,” said Dr Philip Camilleri, clinical director of Urological Cancers at GenesisCare UK, Oxford.

“This treatment allows us to adapt the radiation field to the daily changes in anatomy of the target and the surrounding areas, ensuring that treatment on the MRIdian is as accurate and effective as possible each and every day.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026